Molecular targets of Chinese herbs: a clinical study of hepatoma based on network pharmacology

Scientific Reports

Volumn 6, Issue 1, 2016, Pages

  Gao, Li ^a   Wang, Xiao dong ^b   Niu, Yang yang ^b   Duan, Dan dan ^a   Yang, Xue ^b   Hao, Jian ^b   Zhu, Cui hong ^b   Chen, Dan ^b   Wang, Ke xin ^a   Qin, Xue mei ^a   Wu, Xiong zhi ^b,c  

^a SHANXI UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c TIANJIN PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

GENE EXPRESSION PROFILING; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MEDICINAL PLANT; PHARMACOGENETIC TESTING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS; PHARMACOGENOMIC TESTING; PLANTS, MEDICINAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84983390567     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24944     Document Type: Article

References (47)

1. Salhab, M. & Canelo, R. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther 7, 463–475 (2011).
2. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J Clin 64, 9–29 (2014).
3. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J Clin 65 (2015).
4. Ashtari, S., Pourhoseingholi, M. A., Sharifian, A. & Zali, M. R. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol 7, 1708–1717 (2015).
5. Soerjomataram, I. et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 380, 1840–1850 (2012).
6. Yang, J. D. & Roberts, L. R. Hepatocellular carcinoma: a global view. Nat Rev Gastro Hepat 7, 448–458 (2010).
7. Simard, E. P., Ward, E. M., Siegel, R. & Jemal, A. Cancers with increasing incidence trends in the United States: 1999 through 2008. Ca-Cancer J Clin 62, 118–128 (2012).
8. Lee, J. O. et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol 20, 1402–1407 (2009).
9. Nakamura, M. et al. Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 112, 1765–1771 (2008).
10. Lee, Y. K. et al. Prognostic value of alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. Bmc Cancer 13 (2013).
11. Benson, A. B. 3rd et al. Hepatobiliary cancers, version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN 12, 1152–1182 (2014).
12. Hyodo, I. et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 23, 2645–2654 (2005).
13. Evans, M. A. et al. Men with cancer: is their use of complementary and alternative medicine a response to needs unmet by conventional care? Eur J Cancer Care 16, 517–525 (2007).
14. Swarup, A. B., Barrett, W. & Jazieh, A. R. The use of complementary and alternative medicine by cancer patients undergoing radiation therapy. Am J Clin Oncol-Canc 29, 468–473 (2006).
15. Lee, Y. W. et al. Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: A population-based study. Cancer 120, 1338–1344 (2014).
16. Xu, Y. et al. Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer. Integr Cancer Ther 12, 414–422 (2013).
17. Guo, H. R., Liu, J. X., Xu, L., Madebo, T. & Baak, J. P. A. Traditional Chinese Medicine Herbal Treatment May Have a Relevant Impact on the Prognosis of Patients With Stage IV Adenocarcinoma of the Lung Treated With Platinum-Based Chemotherapy or Combined Targeted Therapy and Chemotherapy. Integr Cancer Ther 10, 127–137 (2011).
18. Man, Y. N., Liu, X. H. & Wu, X. Z. Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma. Chin J Integr Med 21, 49–57 (2015).
19. Zhang, S. X. et al. Gekko-sulfated Glycopeptide Inhibits Tumor Angiogenesis by Targeting Basic Fibroblast Growth Factor. J Biol Chem 287, 13206–13215 (2012).
20. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4, 682–690 (2008).
21. Jia, J. et al. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8, 111–128 (2009).
22. Keith, C. T., Borisy, A. A. & Stockwell, B. R. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4, 71–U10 (2005).
23. Levinson, A. D. Cancer Therapy Reform. Science 328, 137–137 (2010).
24. Schadt, E. E., Friend, S. H. & Shaywitz, D. A. OPINION A network view of disease and compound screening. Nat Rev Drug Discov 8, 286–295 (2009).
25. Li, S. & Zhang, B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med 11, 110–120 (2013).
26. Su, W. H. et al. OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. Nucleic Acids Res 35, D727–D731 (2007).
27. Lee, L. et al. Liverome: a curated database of liver cancer-related gene signatures with self-contained context information. Bmc Genomics 12 (2011).
28. Boige, V. et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 97, 862–867 (2007).
29. Bobbio-Pallavicini, E. et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer 33, 1784–1788 (1997).
30. Uka, K. et al. Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. Oncology-Basel 75, 8–16 (2008).
31. Ueshima, K. et al. Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology-Basel 75 Suppl 1, 106–113 (2008).
32. Okuda, K. et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56, 918–928 (1985).
33. Yeung, Y. P. et al. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 100, 1995–2004 (2005).
34. Manning, B. D. & Cantley, L. C. AKT/PKB signaling: Navigating downstream. Cell 129, 1261–1274 (2007).
35. Liu, L. L. et al. FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget 5, 5113–5124 (2014).
36. Chan, L. K., Chiu, Y. T., Sze, K. M. & Ng, I. O. Tensin4 is up-regulated by EGF-induced ERK1/2 activity and promotes cell proliferation and migration in hepatocellular carcinoma. Oncotarget 6, 20964–20976 (2015).
37. Xu, X. D. et al. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep 11, 25–32 (2004).
38. Yue, X. T. et al. Zinc Fingers and Homeoboxes 2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Represses Expression of Cyclins A and E. Gastroenterology 142, 1559−+ (2012).
39. Kim, K. S. et al. Effects of beta-sitosterol derived from Artemisia capillaris on the activated human hepatic stellate cells and dimethylnitrosamine-induced mouse liver fibrosis. BMC Complement Altern Med 14, 363, doi: 10.1186/1472-6882-14-363 (2014).
40. Zhang, X. J. et al. Autophagy induced by baicalin involves downregulation of CD147 in SMMC-7721 cells in vitro. Oncol Rep 27, 1128–1134 (2012).
41. Ru, J. et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 6, 13 (2014).
42. Xue, R. C. et al. TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis. Nucleic Acids Res 41, D1089–D1095 (2013).
43. Ye, H. et al. HIT: linking herbal active ingredients to targets. Nucleic Acids Res 39, D1055–D1059 (2011).
44. Gong, J. Y. et al. ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method. Bioinformatics 29, 1827–1829 (2013).
45. Zhang, Y. Q. et al. A systems biology-based investigation into the therapeutic effects of Gansui Banxia Tang on reversing the imbalanced network of hepatocellular carcinoma. Sci Rep-Uk 4 (2014).
46. Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L. & Ideker, T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27, 431–432 (2011).
47. Scardoni, G., Petterlini, M. & Laudanna, C. Analyzing biological network parameters with CentiScaPe. Bioinformatics 25, 2857–2859 (2009).